Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolic side effects of olanzapine and ziprasidone strategies in schizophrenia
ChiCTR-OPC-15007529Phase 4Not yet recruiting
- Sponsor
- Xijing Hospital
- Start
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of olanzapine and ziprasidone in schizophrenia and schizophrenia-like syndrome (4 arms), sponsored by Xijing Hospital. Primary endpoints: Change in body weight, Body mass index and 5 more. Planned start Oct 2015; status: not yet recruiting.
02
Drugs
olanzapineziprasidone
03
Conditions
schizophreniaschizophrenia-like syndrome
Beyond the preview
Go deeper on ChiCTR-OPC-15007529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-15007529.